美国安进地舒单抗注射液的效果如何

It is a fully humanized monoclonal antibody that binds and neutralizes RANKL. It specifically binds RANKL with high adhesion and does not bind to other TNF ligands. By neutralizing RANKL, it inhibits the formation, function and survival of osteoclasts, thereby inhibiting osteoclast-mediated bone destruction. So, many patients will ask, how effective is Amgen’s denosumab injection?

In a phase II RCT study randomized to receive subcutaneous injection of 120 mg of denosumab every 4 weeks versus placebo, it was confirmed that the use of denosumab can reduce the osteolytic bone metabolism index uNTx related to bone metastasis SRE. A study on the role of denosumab in postmenopausal hormone receptor-positive, non-metastatic breast cancer receiving adjuvant AI endocrine therapy found that twice-a-year denosumab treatment meaningfully increased bone density and reduced bone resorption, was well tolerated by patients, and had an AE profile comparable to placebo. In addition, denosumab has a rapid onset of action and sustained effects, which is significantly better than the zoledronic acid treatment group. Used twice a year, it will become a new alternative to bisphosphonates for long-term pharmacological treatment to prevent bone loss.

As one of the world's largest biopharmaceutical companies, Amgen is a leader in the global biopharmaceutical industry. It has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry. According to Medical Travel, the current specification of Amgen in the United States is 120 mg, and the price is only $1,450, which is more suitable for patients to use for a long time. Since the exchange rate has been fluctuating for a long time and the price is unstable, please contact Medical Travel for details.